D-peptide Inhibitors of Uropathogenic E. coli Adhesion Proteins to Treat Urinary Tract Infections
尿路致病性大肠杆菌粘附蛋白 D 肽抑制剂治疗尿路感染
基本信息
- 批准号:10932838
- 负责人:
- 金额:$ 4.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AcetylgalactosamineAcuteAdhesionsAffinityAmino AcidsAntibiotic ResistanceAntibiotic TherapyAntibioticsAvidityBacteriaBacterial AdhesinsBacteriophagesBindingBiological AssayBladderBypassCatheterizationCell-Matrix JunctionCellsChemicalsChronicCircular DichroismCircular Dichroism SpectroscopyCollaborationsComplexConsensus SequenceCytoplasmDisease ProgressionDrug Delivery SystemsDrug KineticsDrug resistanceFiltrationFluorescence PolarizationGalactoseGoalsGrowthHalf-LifeHemagglutinationImageImmune responseInfectionInflammationInjectionsKidneyKnowledgeLawsLeadLectinLibrariesLigationLower urinary tractMammalian CellMannoseMeasuresMediatingMethodsMicrobial BiofilmsModelingMolecular ConformationMonitorMusOutputPathogenesisPeptide HydrolasesPeptide Phage Display LibraryPeptide SynthesisPeptidesPeriodicityPhage DisplayPhasePilumPopulationProteinsRandomizedRecombinant ProteinsRecombinantsRecurrenceReportingResearchRiskRisk ReductionSecondary Protein StructureSolidSpecificityStructureSurfaceTransitional EpitheliumTreatment EfficacyUrinary tractUrinary tract infectionUrinationUrineUropathogenic E. coliValidationVirulenceWomanX-Ray Crystallographyalternative treatmentantimicrobialbacterial communitychemical synthesiscommensal bacteriacostcytotoxicitydeep sequencingdesignefficacy evaluationefficacy studyenantiomerfitnessglycomimeticsgut microbiomegut microbiotaimmune clearanceimmunogenicityimprovedin vitro Assayin vivoinhibitorkidney cellmouse modelnext generation sequencingnovelpeptide Lpeptide chemical synthesispreventrecurrent infectionresistant strainscreeningvaginal microbiota
项目摘要
PROJECT SUMMARY
Adhesion proteins on the pilus-covered surface of Uropathogenic E. coli (UPEC) are required for attachment
to host cells to facilitate colonization and disease progression in urinary tract infections (UTIs). The primary
adhesion proteins associated with UPEC virulence are FimH, which binds D-mannose on uroepithelial cells, and
FmlH, which binds N-acetylgalactosamine on kidney and inflamed bladder cells. This proposal aims to develop
UTI treatments that prevent the attachment and subsequent internalization of UPEC in uroepithelial cells,
eliminating bacteria from the urinary tract. Treatments that block the highly conserved binding pockets of
FimH/FmlH prevent UPEC attachment to host cells and clear bacteria from the urinary tract6,9,11. However,
designing inhibitors that reach the urinary tract to reduce the risk for recurrent infections (e.g., through a long
half-life and without disrupting commensal bacteria) remains challenging. Our goal is to use mirror-image phage
display to identify D-peptide inhibitors of UPEC adhesion to eliminate bacteria from the urinary tract. We
hypothesize that D-peptide inhibitors that prevent attachment to host cells could serve as novel
antibiotic-sparing UTI treatments. D-peptides are ideal for this application because they are cleared via kidney
filtration (accumulate in urine), have a long half-life, and can be formulated as a long-acting injection.
To screen for D-peptide inhibitors, we will first chemically synthesize the mirror-image D-target proteins
(FimH/FmlH) using solid-phase peptide synthesis (SPPS) with D-amino acids and native chemical ligation (NCL).
These D-proteins will be validated by comparison to recombinant L-proteins for secondary structure and binding
activity. Using mirror-image phage display, we will screen diverse phage libraries for L-peptide binders to the
synthesized D-target proteins. Next-generation sequencing (NGS) will be used to identify high-affinity hits that
will then be synthesized in D- to inhibit the natural L-target.
We will determine the affinity of our inhibitors via direct binding and competition studies. The crystal structures
of our D-peptides in complex with FimH or FmlH will be obtained using X-ray crystallography and will inform
inhibitor affinity optimization. In vitro assays will be performed using a panel of 40 UPEC strains to validate D-
peptide inhibition of host cell attachment, hemagglutination, and biofilm formation. We will determine the
pharmacokinetic (PK) profile of the most promising D-peptides in mice. Finally, we will evaluate the efficacy of
treatments in mouse acute and chronic UTI models. This project will contribute valuable information about UPEC
pili binding interactions, advance our chemical protein synthesis knowledge, and generate D-peptide inhibitor
leads for precision UTI treatment.
项目摘要
尿致病性E.大肠杆菌(UPEC)是附着所必需的
宿主细胞以促进尿路感染(UTI)中的定殖和疾病进展。主
与UPEC毒力相关的粘附蛋白是FimH,其结合尿上皮细胞上的D-甘露糖,
FmlH,其结合肾脏和发炎膀胱细胞上的N-乙酰半乳糖胺。该提案旨在发展
防止UPEC在尿路上皮细胞中附着和随后内化的UTI治疗,
清除尿路中的细菌。阻断高度保守的结合口袋的治疗
FimH/FmlH阻止UPEC附着于宿主细胞并从尿路清除细菌6,9,11。然而,在这方面,
设计到达泌尿道的抑制剂以降低复发感染的风险(例如,通过长
半衰期和不破坏肠道细菌)仍然具有挑战性。我们的目标是利用镜像噬菌体
显示以鉴定UPEC粘附的D-肽抑制剂,从而从泌尿道中消除细菌。我们
假设阻止附着于宿主细胞的D-肽抑制剂可以作为新的
泌尿生殖道感染治疗。D-肽是这种应用的理想选择,因为它们可以通过肾脏清除
过滤(积聚在尿液中),半衰期长,可配制成长效注射剂。
为了筛选D肽抑制剂,我们将首先化学合成镜像D靶蛋白
(FimH/FmlH),使用具有D-氨基酸和天然化学连接(NCL)的固相肽合成(SPPS)。
这些D蛋白将通过与重组L蛋白的二级结构和结合进行比较来验证
活动利用镜像噬菌体展示,我们将筛选不同的噬菌体库中的L-肽结合剂,
合成D-靶蛋白。下一代测序(NGS)将用于鉴定高亲和力命中,
然后会在D-中合成以抑制天然的L-目标。
我们将通过直接结合和竞争研究确定我们的抑制剂的亲和力。晶体结构
我们的D-肽与FimH或FmlH的复合物将使用X射线晶体学获得,并将告知
抑制剂亲和力优化。将使用一组40种UPEC菌株进行体外试验,以验证D-
肽抑制宿主细胞附着、血凝和生物膜形成。康贝特人将以
图1显示了小鼠中最有希望的D-肽的药代动力学(PK)曲线。最后,我们将评估
在小鼠急性和慢性UTI模型中的治疗。该项目将为UPEC提供有价值的信息
皮利结合相互作用,推进我们的化学蛋白质合成知识,并产生D-肽抑制剂
用于精确UTI治疗的导线。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marcy Robins其他文献
Marcy Robins的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 4.12万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 4.12万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 4.12万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 4.12万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 4.12万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 4.12万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 4.12万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 4.12万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 4.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 4.12万 - 项目类别:
Operating Grants